Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Tysabri – Therapeutic Monoclonal Antibody (Mab) for the Treatment of Multiple Sclerosis

Drug (brand / generic)

Tysabri (natalizumab)

Company / Licensee

Elan Pharmaceuticals/ Biogen

Therapy Class

Selective Adhesion-Molecule Inhibitor

Product Description

Alpha-4 antagonist

Current Indication

Treatment of multiple sclerosis

Market Sector

CNS

Development Status

Launched US end 2004; recalled February 2005; reintroduced July 2006. Approved Europe
Expand

Go Top